May 1 (Reuters) - Amgen Inc AMGN.O:
AMGEN Q1 ADJUSTED EPS $4.90 VERSUS IBES ESTIMATE $4.30
AMGEN Q1 TOTAL REVENUE $8.15 BILLION VERSUS IBES ESTIMATE $8.06 BILLION
AMGEN OUTLOOK FY TOTAL REVENUE $34.3 BILLION TO $35.7 BILLION VERSUS IBES ESTIMATE $35.09 BILLION
AMGEN: 2025 SHARE REPURCHASES NOT TO EXCEED $500 MILLION
AMGEN: 2025 OUTLOOK INCLUDES ESTIMATED IMPACT OF IMPLEMENTED TARIFFS, BUT DOES NOT ACCOUNT FOR ANY FUTURE LEVIES
AMGEN OUTLOOK FY ADJUSTED EPS $20.00 TO $21.20 VERSUS IBES ESTIMATE $20.64
AMGEN: PHASE 1 STUDY OF AMG 513 ENROLLING PEOPLE LIVING WITH OBESITY AFTER REMOVAL OF CLINICAL HOLD BY U.S. FDA
Further company coverage: AMGN.O
((( Reuters.Briefs@thomsonreuters.com );))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.